Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer.

Autor:	Kao YC; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Tsai YF; Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Shen SC; Division of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC., Dai MS; Division of Hematology and Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC., Chen FM; Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC., Liu LC; Department of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC., Chao TC; Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Huang CC; Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Hou MF; Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC., Chen SC; Division of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC., Liu CY; Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Tseng LM; Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Jazyk:	angličtina
Zdroj:	Journal of the Chinese Medical Association : JCMA [J Chin Med Assoc] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
DOI:	10.1097/JCMA.0000000000001189
Abstrakt:	Background: Everolimus was the first orally targeted therapy for certain cancers. It was introduced before CDK4/6 inhibitors and is widely used to treat advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This study presents comprehensive findings including updated data and long-term survival analyses focusing on patients with HR+/HER2- metastatic breast cancer who received everolimus-based treatment. The objectives were to assess the impact of everolimus on overall survival (OS) and progression-free survival (PFS) by treatment line, and to evaluate its role in therapeutic strategies in a real-world setting. Methods: We included 299 women aged over 20 years with histologically confirmed HR+/HER2- breast cancer who received everolimus-based treatment from multiple medical centers in Taiwan. Survival curves were generated using the Kaplan-Meier method, with the log-rank test for comparisons. Univariate and multivariate analyses were performed using a Cox proportional hazards regression model. Adverse effects were graded according to the Common Terminology Criteria for Adverse Events version 5.0. Results: The median PFS was 5.6 months, and the median OS was 60.1 months. Patients receiving everolimus treatment in three or more lines and those who underwent chemotherapy prior to everolimus-based treatment had a significantly shorter PFS but longer OS. Patients with liver and central nervous system metastases had significantly shorter PFS and OS. The disease control rate was 51.5%, and the overall response rate was 8.0%. Conclusion: These findings support current guidelines and advocate for the inclusion of everolimus in treatment plans for patients with metastatic HR+/HER2- breast cancer, particularly in late-line treatment, with careful consideration of the benefit-risk profile for each patient. Competing Interests: Conflicts of interest: Dr. Chun-Yu Liu and Dr. Ling-Ming Tseng, editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. (Copyright © 2024, the Chinese Medical Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu